Abstract
Background: The novel SARS-CoV-2 pandemic has inflicted a major blow on public health worldwide accounting for millions of deaths and subsequent socio-economic consequences. The main challenge for scientists and researchers has been to restrain transmission of the virus and prevent severe respiratory disease. Novel promising vaccines aim to fulfil these expectations, although new variants of the coronavirus have emerged. The present manuscript aims to add to the knowledge, through a case of an immunodeficient patient, who developed remarkably favorable recovery from SARS-CoV-2 pneumonia after having been fully vaccinated against the novel coronavirus. Case presentation: An 82-year-old Caucasian male with a history of metastatic pancreatic cancer was admitted with signs and symptoms of pneumonia. Workup revealed a positive SARS-CoV-2 real time – polymerase chain reaction (RT-PCR) and further investigation identified a B.1.1.7 variant. The imaging essays showed extensive lung disease. Interestingly, the patient had already received the second dose of the BNT162b2 (Pfizer) vaccine against the new coronavirus 16 days prior. After having been treated with appropriate antiviral and antibiotical agents the patient showed significantly favorable recovery and no need for high oxygen flows and no complications presented. The patient was discharged after six days of hospitalization in good condition, with no need for supplementary oxygen at home. Conclusions: Despite breakthrough cases, vaccination against COVID-19 is crucial for restraining the novel coronavirus. Further studies should be carried out in order to determine the optimal strategies for large-scale vaccination while minimizing the risk of further and faster evolution of the virus.
Highlights
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is responsible for approximately three million deaths, and subsequent vast financial and social burdens due to the current global pandemic.[1]
The rapid and wide utilization of effective, and safe vaccines against SARS-CoV-2 infection and COVID-19 that act against viral infection, disease, transmission, and death is essential for the establishment of public health internationally.[1,2]
With emphasis on the present efficacy endpoint, the present manuscript aims to add to the existing knowledge, while presenting the case of an immunodeficient patient, who developed remarkably favorable outcomes from SAR-CoV-2 pneumonia after having been fully vaccinated against the novel coronavirus
Summary
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is responsible for approximately three million deaths, and subsequent vast financial and social burdens due to the current global pandemic.[1]. The patient’s medical history included pancreatic cancer with lung metastasis, prostate hyperplasia, and frequent RBC transfusions. His last chemotherapy session had taken place two weeks ago and he had received the second dose of the BNT162b2 (Pfizer) vaccine against COVID-19 16 days prior. Both doses had been administered without any complications. We preceded to admission of the patient for appropriate treatment This included remdesivir 200 mg at first day of admission 100 mg once daily, ceftriaxone 2 gr once daily, levofloxacin 500 mg once daily,
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
